{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-25-000183","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2025-09-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.824479+00:00","generated_at":"2026-05-17T07:54:59.479915+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Emergent BioSolutions awarded $30M BARDA contract modification for CYFENDUS anthrax vaccine","bullets":["Modification No. 20 valued at $30M for additional doses of CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted).","Deliveries begin calendar 2025 and are scheduled to be completed by March 2026.","Follows a prior $50M modification in December 2024 for the same vaccine.","CYFENDUS received FDA approval in July 2023 as a two-dose post-exposure prophylaxis for adults 18-65."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-25-000183","json":"https://secwatch.observer/filing/0001367644-25-000183.json","markdown":"https://secwatch.observer/filing/0001367644-25-000183.md","text":"https://secwatch.observer/filing/0001367644-25-000183.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764425000183/0001367644-25-000183-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764425000183/ebs-20250902.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T07:54:59.479915+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}